Virax Biolabs Introduces Human Papillomavirus Test Kit

Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.